Zoltán Mátrai

机构：National Institute of Oncology · ORCID：0000-0003-4104-108X

发表论文 66 篇 · 总被引 1054 次 · h-index 17

代表论文

• Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL (2020 · Nature Communications · 被引 98)
• Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib (2019 · International Journal of Cancer · 被引 56)
• Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (2022 · Leukemia · 被引 55)
• Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 39)
• Screening and monitoring of the BTK C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy (2021 · British Journal of Haematology · 被引 21)
• BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024 · Blood · 被引 20)